Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PLUS THERAPEUTICS, INC. | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K/A
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2015
CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-34375
|
33-0827593
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
3020 Callan Road, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 458-0900
(Registrant's telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note: As previously disclosed in the Current Report on Form 8-K filed on March 4, 2015, Cytori Therapeutics, Inc. (the “Company”) presented at the the 35th Annual Cowen and Company Health Care Conference on March 4, 2015. The presentation, filed as Exhibit 99.1 to the Form 8-K, contained certain typographical errors. The Company hereby amends such Form 8-K to correct the typographical errors. The revised presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K/A and is incorporated herein by reference.
Item 2.02 Results of Operations and Financial Condition
As reported in Item 7.01, attached as Exhibit 99.1 to this Current Report on Form 8-K is a presentation that Cytori Therapeutics, Inc. (the “Company”) intends to use at the 35th Annual Cowen and Company Health Care Conference and for other corporate purposes. The presentation includes certain information about the Company’s results of operations and financial condition as of December 31, 2014 (unaudited).
Item 7.01 Regulation FD Disclosure
Attached as Exhibit 99.1 to this Current Report on Form 8-K is a presentation that the Company intends to use at the 35th Annual Cowen and Company Health Care Conference and for other corporate purposes. Additionally, the Company has posted the slide presentation on the Company's Investor Relations website at http://ir.cytori.com.
The information contained in Items 2.02 and 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
Exhibit 99.1
|
Cytori Therapeutics, Inc. Presentation (previously filed, revised to correct typographical errors)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CYTORI THERAPEUTICS, INC.
|
|
|
Date: March 4, 2015
|
By: /s/ Tiago Girao
|
|
Tiago Girao
|
|
|
VP Finance and Chief Financial Officer
|
Exhibit Index
|
Exhibit Number
|
Description
|
|
Cytori Therapeutics, Inc. Presentation
|